About Simulations Plus Inc.

Simulations Plus Inc., founded in 1996, has become the leading provider of modeling and simulation software that helps pharmaceutical companies optimize drug development processes. The company's sophisticated algorithms predict drug behavior in the human body, reducing development time and costs. SLP stock price reflects the company's essential role in modern drug development and the growing adoption of modeling and simulation in pharmaceuticals.

Led by founder and CEO Shawn O'Connor, Simulations Plus has consistently innovated while building a comprehensive platform of modeling and simulation tools. The management team's deep scientific expertise and commitment to R&D has maintained the company's technology leadership. Leadership's strategic focus on expanding capabilities through acquisitions and organic development has been crucial for serving evolving customer needs and driving SLP stock price appreciation.

Simulations Plus operates by developing and marketing software products and consulting services that model drug absorption, distribution, metabolism, and toxicity, enabling pharmaceutical companies to make better decisions earlier in drug development. The company's tools are used by leading pharmaceutical and biotechnology companies worldwide. With increasing pressure to reduce drug development costs and timelines, growing regulatory acceptance of modeling approaches, and Simulations Plus' established market leadership and expanding product portfolio, SLP offers investors exposure to essential pharmaceutical technology with strong recurring revenue characteristics and significant growth potential as computational approaches become increasingly integral to drug development.